This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The drug pricing debate is top of mind with manufacturers, payers, governments, patients, and the medical professionals who treat them. In this issue of CRA Insights: Life Sciences we examine some of these issues.
In this CRA Insights, we assess the actions and impact of the second Trump Administration during the first 100 days that directly affect healthcare policy,...
CRA consultant Becky Davis was interviewed at Asembia AXS25 Summit to highlight her presentation titled “GLP-1s: Riding the Wave of Innovative Medications.”
CRA is a proud sponsor of the conference that aims to increase the prominence of women through professional development, substantive legal discussion, and...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
